The AI Data Center Pivot, and Capricor's FDA Roadblock
I'm LongbridgeAI, I can summarize articles.Hyperscale Data abandons crypto for a massive AI bet, while Capricor faces a regulatory delay. Plus, HUTCHMED's billion-dollar GSK pact and more strategic shifts across biotech and commodities.
In the rush to capitalize on the artificial intelligence infrastructure boom, the pivot away from legacy tech is becoming ruthless. This September, Hyperscale Data (GPUS.US) officially pulled the plug on its Michigan Bitcoin mining operations. The reason? A massive reallocation of resources to fulfill a USD 1.2 billion AI data center master service agreement. It's a stark reminder of where the capital is flowing, especially as the company sets a USD 750 million minimum sale threshold for the facility. Meanwhile, LightPath Technologies (LPTH.US) is securing its own strategic wins, landing a DoD prototype agreement for germanium alternatives this fall shortly after divesting its China operations.
Regulatory timelines, meanwhile, are proving just as volatile for the biotech sector. Capricor Therapeutics (CAPR.US) saw the FDA push its target action date for its Duchenne muscular dystrophy cell therapy to late November 2026 following major data submission revisions. On the flip side, HUTCHMED (HCM.US) just locked in a massive win, striking an exclusive licensing agreement with GSK for an ADC drug that could yield over USD 1.1 billion in milestone payments. Burning Rock Biotech (BNR.US) is facing a bumpier road, navigating shrinking central lab revenues in Q2 2026 even as its in-hospital diagnostic business shows resilience.
The Also
- HF Sinclair (DINO.US) is spinning off its lubricants division and retooling its supply chain with SK Enmove and Chevron, following a solid Q2 2026 earnings beat.
- Northern Dynasty Minerals (NAK.US) remains in legal limbo, waiting on a federal court decision regarding the EPA's veto of its Alaskan Pebble copper and gold project.
- Adidas (ADDYY.US) is projecting 9% to 10% constant-currency revenue growth for 2026, though a massive 30% jump in marketing spend has kept some analysts cautious about structural risks.
- Fidelity US Bond Index ETF (FIGG.US) is tilting slightly toward riskier assets like high-yield and leveraged loans, navigating the shifting 2026 credit market environment.
- iShares Preferred and Income Securities ETF (PFF.US) continues to offer a steady pipeline for yield-seekers, maintaining a reliable trailing twelve-month payout profile into the late summer of 2026.